Christopher Raymond
Stock Analyst at Raymond James
(2.69)
# 1,872
Out of 5,163 analysts
142
Total ratings
52.14%
Success rate
1.54%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Strong Buy | $46 | $24.81 | +85.41% | 1 | Mar 11, 2026 | |
| CLYM Climb Bio | Initiates: Strong Buy | $25 | $7.03 | +255.62% | 1 | Mar 11, 2026 | |
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $34.00 | +52.94% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $5.78 | +176.82% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $6.66 | +275.38% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.49 | +189.53% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.39 | +292.42% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $115.50 | -39.39% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $181.55 | -36.66% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.98 | +354.55% | 6 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $126 | $58.51 | +115.35% | 15 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $4 | $6.82 | -41.35% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $219.68 | +3.33% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $469.34 | +13.56% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $745.77 | +35.83% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $21.34 | +556.04% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $60.36 | +19.28% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.54 | +267.23% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.85 | +855.41% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.58 | +693.32% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.19 | +5,121.93% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $36.22 | -8.89% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.46 | +173.97% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $366.21 | -21.36% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.85 | +47.22% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $37.99 | -26.30% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $97.93 | -59.15% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $7.31 | +1,131.19% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.66 | +5,683.13% | 2 | Mar 13, 2020 |
Alumis
Mar 11, 2026
Initiates: Strong Buy
Price Target: $46
Current: $24.81
Upside: +85.41%
Climb Bio
Mar 11, 2026
Initiates: Strong Buy
Price Target: $25
Current: $7.03
Upside: +255.62%
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $34.00
Upside: +52.94%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $5.78
Upside: +176.82%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $6.66
Upside: +275.38%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.49
Upside: +189.53%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.39
Upside: +292.42%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $115.50
Upside: -39.39%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $181.55
Upside: -36.66%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.98
Upside: +354.55%
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.51
Upside: +115.35%
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $6.82
Upside: -41.35%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $219.68
Upside: +3.33%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $469.34
Upside: +13.56%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $745.77
Upside: +35.83%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $21.34
Upside: +556.04%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $60.36
Upside: +19.28%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.54
Upside: +267.23%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.85
Upside: +855.41%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.58
Upside: +693.32%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.19
Upside: +5,121.93%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $36.22
Upside: -8.89%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.46
Upside: +173.97%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $366.21
Upside: -21.36%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.85
Upside: +47.22%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $37.99
Upside: -26.30%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $97.93
Upside: -59.15%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $7.31
Upside: +1,131.19%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.66
Upside: +5,683.13%